tbuckley/cabot-search huggingface dataset:
Clinical outcomes in patients with castrate-refractory prostate cancer (CRPC) metastatic to bone randomized in the factorial trapeze trial to docetaxel (D) with strontium-89 (Sr89), zoledronic acid (ZA), neither, or both (ISRCTN 12808747).
Authors: Nicholas David James, Sarah Pirrie, Darren Barton, Janet Elizabeth Brown, Lucinda Billingham, Stuart I. Collins, Adam Daunton, Alison J. Birtle, Prabir Ranjan Chakraborti, Daniel Ford, Syed A. Hussain, Helen Jones, Ann Pope, Emilio Porfiri, John Martin Russell, Andrew Stanley, John Staffurth, Duncan McLaren, Chris Parker, James Wylie
Journal: Journal of Clinical Oncology (2013)

LBA5000 The full, final text of this abstract will be available at abstract.asco.org at 7:30 AM (EDT) on Sunday, June 2, 2013, and in the Annual Meeting Proceedings online supplement to the June 20, 2013, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Sunday edition of ASCO Daily News.
The Miami Beach Clinical Convention
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Prospective study of replacing administration sets for intravenous therapy at 48- vs 72-hour intervals. 72 hours is safe and cost-effective
Authors: D. G. Maki
Journal: JAMA (1987)

We prospectively studied the safety of replacing intravenous delivery systems, including those used in total parenteral nutrition, at 72- compared with 48-hour intervals in 487 patients. Although the prevalence of contamination of intravenous fluid was higher in administration sets replaced at 72-hour intervals (10/664,1.5%) than in sets replaced every 48 hours (6/710,0.8%), the difference is not statistically significant. Contamination in both groups was almost exclusively with small numbers of coagulase-negative staphylococci (range, 1 to 27 colony-forming units/mL); no contaminated infusion was associated with clinical signs of sepsis or concordant bacteremia. Contaminants were recovered less frequently from peripheral venous infusions (0.6%) than from infusions used for central venous access or hemodynamic monitoring (1.5%) or total parenteral nutrition (3.6%); infusions in an intensive care unit were more frequently contaminated (2.5%) than infusions on medical and surgical wards (0.9%). These data indicate that extrinsic contamination of intravenous fluid is a rare cause of endemic nosocomial septicemia, and for most infusions it is unnecessary to routinely replace delivery systems more frequently than every 72 hours. (<i>JAMA</i>1987;258:1777-1781)
Accredited Sponsors of Continuing Medical Education
Journal: JAMA (1976)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
UNUSUAL COMPLICATIONS OF MEASLES.
Journal: JAMA (1904)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Duration of relaxation after intramuscular neurolysis with phenol
Authors: D. Halpern
Journal: JAMA (1967)

After localization of electrically sensitive points in hypertonic muscles, it was possible in all but 20 of 394 muscles in 95 patients to achieve significant relaxation resulting in improved function or posture with intramuscular chemical neurolysis. Injections of dilute phenol solution in small amounts were used. The injections can be repeated, and relaxation has been maintained by a single series or multiple series of injections as long as a year to 17 months. Relaxation persisted six months or longer in 60% of the muscles injected and four months or longer in 84%.
Meningococcal Conjunctivitis
Authors: J. D. A. Gray, R. A. Lambert
Journal: BMJ (1949)

Hitherto there has been no evidence that the human louse can act as a vector of Treponema duttoni in nature.Even in the laboratory Nicolle and Anderson (1927) were unable to infect lice with a Congo strain of the parasite.Recently, however, Heisch and Garnham (1948) have shown that under laboratory conditions several strains of East African T. duttoni can infect and undergo metacyclic development in lice, and that the infection can be transmitted by inoculation.The present paper reports the discovery of natural infections in lice of spirochaetes indistinguishable from T. duttoni.rhe only other worker to have experimented along these lines is Blanchard (1914), who in the Congo inoculated mice with lice collected from patients infected by T. duttoni, but with negative results.Lice were collected from the clothes of patients infected with T. duttoni at Kisumu and other places in Kenya Colony where the disease is endemic; after being kept for varying periods they were emulsified with saline and inoculated into rats and mice.Lice were collected from seven patients, and four of the batches proved infective.Case 1.-Ten lice (L19) were collected on Aug. 26, 1946.
ATIM-18. A PHASE I TRIAL OF HYPOFRACTIONATED STEREOTACTIC IRRADIATION (HFSRT) WITH PEMBROLIZUMAB AND BEVACIZUMAB IN PATIENTS WITH RECURRENT HIGH GRADE GLIOMA (NCT02313272)
Authors: Solmaz Sahebjam, Peter Forsyth, John Arrington, Michael Jaglal, Nam D Tran, Arnold B Etame, Melissa Wicklund, Ali Drury-Sibiga, Wendy Long, Brittany Evernden, Tyra Gatewood, Robert Macaulay, Prakash Chinnaiyan, Michael Yu
Journal: Neuro-Oncology (2017)

There is strong pre-clinical evidence for the combination of PD-1 blockade with radiotherapy and anti-VEGF therapy. Herein, we present safety and efficacy data from a phase 1 study combining pembrolizumab, an anti-PD-1 monoclonal antibody, with hypofractionated stereotactic irradiation (HFSRT) and bevacizumab in recurrent high grade glioma. This phase I study (3 + 3 design) explored the safety, tolerability, recommended phase II dose (RP2D), and antitumor activity of pembrolizumab administered concurrently with HFSRT and bevacizumab. Adult patients with recurrent glioblastoma or anaplastic astrocytoma (maximum diameter of target lesion ≤ 3.5 cm) were eligible. Eligible patients received HFSRT to the recurrent tumor (30 Gy in 5 fractions) combined with bevacizumab (10 mg/kg, Q2W) and pembrolizumab (100 mg or 200 mg intravenously based on dose level, Q3W). Two dose levels of pembrolizumab were explored and 20 patients were treated at RPD2. Treatment continued until disease progression or unacceptable toxicity. Twenty three patients with recurrent glioblastoma have been treated on this study (3 patients at 100 mg and 20 patients at 200 mg dose levels). Five patients had previous tumor progression on bevacizumab. Combination of HFSRT with pembrolizumab (200 mg every 3 weeks) and bevacizumab was generally well tolerated. The most common toxicities were grade 1 fatigue and grade 1 proteinuria. No treatment-related neurologic adverse events were observed. In 1 patient, study treatment was discontinued due to grade 3 elevation of liver transaminases. Durable objective responses (complete response + partial response ≥ 6 months) were observed in 53% of patients. The overall survival rate (at the time of abstract submission) at 6 and 12 months were 94% (16 out of 17 patients) and 64% (7 out of 11 patients), respectively. Combination of HFSRT with pembrolizumab (200 mg every 3 weeks) and bevacizumab is safe. Clinical activity of this combination therapy is encouraging.
Hand-Atlas of Clinical Anatomy.
Journal: JAMA (1925)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
FOREIGN CORRESPONDENCE.
Journal: JAMA (1883)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Cancer outcomes at end of life in Michigan.
Authors: M. Darwish-Yassine, S. Affholter, J. Towns, J. W. Finn
Journal: Journal of Clinical Oncology (2010)

9037 Background: End-of-life care is an important focus of comprehensive cancer control. In previous ASCO abstracts we reported 2004 and 2006 data. This abstract provides an update with the 2008 survey results. Methods: A population-based sample of caregivers, age 40 and older, including minorities, were contacted by trained staff (bilingual) using computer-assisted telephone interviews. Results: 993 respondents constituted the sample size of caregivers who reported having cared for a family member who died of a terminal illness within the past 5 years, including 225 African Americans, 114 American Indian, 92 Hispanic Americans, 69 Arab Americans and 51 Asian Americans. 58.1% died of cancer. The average pain level in the final 3 months was severe to excruciating for 43.0% (56.1% for cancer decedents). Pain medications had been prescribed for 91.8%; however, not used as directed for 22.0%. The most frequent reason given for this was “felt worse/side effects” (62.1%); “fear of addiction” (4.7%) and “cost” (0.3%). The proportion who died at home was 82.4%. Hospice utilization in the last 3 months of life for those who died of cancer was 75.2% (57.9% non-cancer deaths), but lower in all minority groups except Hispanic Americans. The median length-of-stay in hospice continues to be short, 16.1 days in 2008 versus 16.0 in 2006. The main reason given why hospice was not chosen was that death occurred before hospice enrollment (35.6%). 26.5% of caregivers rated their own stress level as severe to unbearable. Name recognition of palliative care is improving (18.6% up from 1% in 2006). Conclusions: Cancer outcomes data at end-of-life is an important part of state-wide comprehensive cancer control. The follow-up data suggest ongoing challenges in regards to cancer pain management in the state as well as timeliness of hospice utilization (and minority access). Of note is the reported stress experienced by caregivers and the increasing recognition of the term, palliative care. No significant financial relationships to disclose.
PAPERS FOR THE ANNUAL MEETING.
Journal: JAMA (1890)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 699: KMT2A regulates cervical cancer cell growth andapoptosisthrough cooperation with VDAC1
Authors: Changlin Zhang, Yizhuo Li, Qian Long, Tianze Liu, Ge Qin, Dingbo Shi, Miao Chen, Kefang Zhang, Shuihan Shi, Wuguo Deng
Journal: Cancer Research (2019)

Abstract Cervical cancer is an aggressive cutaneous malignancy, illuminating the exact mechanisms of tumorigenesis and discovering novel therapeutic targets are urgently needed. Lysine methyltransferase 2A (KMT2A) is a transcriptional co-activator regulating gene expression during early development and hematopoiesis, but the role of KMT2A in cervical cancer remains largely unknown. Here, we showed that KMT2A regulated cervical cancer cell growth and apoptosis through cooperation with VDAC1 (voltage dependent anion channel 1). Knockdown of KMT2A significantly inhibited cell viability and cell migration and induced apoptosis in cervical cancer cells. Overexpression of VADC1 reversed the KMT2A knockdown-mediated suppression of cell viability and cell migration and induction of apoptosis. The results from a xenograft mouse model confirmed that KMT2A regulated cervical cancer growth via the VDAC1 signaling. Moreover, analyses of clinical samples demonstrated that the expression of KMT2A and VDAC1 were positively correlated in cervical cancer tissues, especially in cervical intraepithelial neoplasia (CIN) samples. Collectively, our results indicated that KMT2A promoted cervical cancer growth by cooperating with the VDAC1, suggesting that the KMT2A/VDAC1 signaling pathway may be a potential therapeutic target for cervical cancer. Citation Format: Changlin Zhang, Yizhuo Li, Qian Long, Tianze Liu, Ge Qin, Dingbo Shi, Miao Chen, Kefang Zhang, Shuihan Shi, Wuguo Deng. KMT2A regulates cervical cancer cell growth andapoptosisthrough cooperation with VDAC1 [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 699.
PLoS Medicine Issue Image | Vol. 5(4) April 2008
Journal: PLoS Medicine (2008)

Transparency in the conduct and reporting of health research is the concern of this month's editorial, which announces the launch of the new Guidelines and Guidance section in PLoS Medicine. The section will include articles that raise awareness of new methodological approaches, community standards for reporting and carrying out research, and guides to approaching statistical and methodological issues. Proposals for papers to be considered for this section can be entered through our presubmission system. PLoS Medicine has actively promoted standards to improve the conduct and quality of research, including papers detailing the STROBE guidelines for observational studies (von Elm, et al. e296; Vandenbroucke, et al. e297) and the CONSORT statement for abstracts of randomized controlled trials (Hopewell, et al. e20). As the editorial mentions, the new section is timely, given the inaugural meeting of the EQUATOR (Enhancing the Quality and Transparency of Health Research) network in June, an initiative to provide resources and training relating to good research reporting. Image Credit: Globes at the Museum of Communication, Berlin, by tuppus
Respiratory disease in coal miners
Authors: W. K. Morgan
Journal: JAMA (1975)

LAST year the Social Security Administration disbursed more than $1 billion for "black lung" compensation. By way of comparison, for 1971 the total disbursement for all other industrial injury and illness for the entire US population covered by workmen's compensation laws was only $2.4 billion. Yet, there are around 120,000 working coal miners as compared to approximately 30 to 40 million other US workers covered by workmen's compensation laws. Nor can this disparity be explained by the fact that a disabled miner receives almost twice as much in compensation as does a disabled steelworker with silicosis. The Federal Coal Mine Health and Safety Act of 1969, and the regulations that were put into effect as the result of the passage of this act, enabled any coal miner to qualify for "black lung" benefits provided he had (1) roentgenographic evidence of complicated pneumoconiosis (progressive massive fibrosis [PMF]); (2) simple pneumoconiosis in
Genug Syndrome
Authors: Jennifer M Soyke
Journal: JAMA (2008)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Renal pseudotumor due to infolding column of Bertin
Authors: M. M. Kyaw
Journal: JAMA (1972)

<h3>To the Editor.—</h3> In spite of a few welldocumented reports in the literature on this recently popularized entity of renal pseudotumors,<sup>1-5</sup>the one due to the infolding renal column of Bertin is still not widely known. Consequently, patients have been subjected to unnecessary surgical procedures for this innocent apparent renal mass lesion.<sup>1,3</sup>Although the pyelographic appearance may suggest a mass in the kidney, the diagnosis of pseudotumor consisting of normal renal parenchyma can be easily established by renal angiogram. Obviously, awareness and recognition of pseudotumor due to infolding renal column is extremely important, so that the apparent mass consisting of normal parenchymal tissues is not mistakenly diagnosed as neoplasm. <h3>Report of a case.—</h3> This is a 22-year-old man who was found to be hypertensive during routine physical examination. The patient was completely asymptomatic and particularly denied having any symptoms referrable to the genitourinary system. The past history was